Literature DB >> 8236136

Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.

A Tripodi1, V Chantarangkul, A A Arbini, M Moia, P M Mannucci.   

Abstract

Hirudin prolongs the APTT when added to normal plasma and the extent of prolongation depends on the type of reagent used. The aim of this study was to compare the dose-response curves of 10 widely used APTT reagents for linearity and parallelism. On each of 10 working days a normal pooled plasma was mixed with increasing amounts of recombinant hirudin (HBW023) ranging from 0 to 5 micrograms/ml and tested for APTT by photo optical coagulometer. Within each working day, clotting times were measured in duplicate and the order of testing with each reagent was changed every day. Results were expressed as ratios of clotting times with hirudin to clotting times without hirudin, and the values plotted against the hirudin concentration on a log-log scale. The dose-response curves for all reagents were linear over 0.3-1.2 micrograms/ml. The reagent-related slopes ranged from 0.225 +/- 0.003 to 0.303 +/- 0.003 (mean +/- SE) and were significantly different. Precision studies indicated that the least sensitive reagent was also the least precise. These findings indicate that the clotting time values obtained for patients treated with hirudin will vary depending on the APTT reagent used.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8236136

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393).

Authors:  P Thürmann; S Harder; C M Kirchmaier
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 2.  Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin.

Authors:  M Monreal; J Costa; P Salva
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

3.  Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.

Authors:  M Cullberg; U G Eriksson; M Larsson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

Review 4.  Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?

Authors:  John W Eikelboom; John French
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Reversible crystallization of argatroban after subcutaneous application in pigs.

Authors:  Mercedes Lopez; Goetz Nowak
Journal:  Thrombosis       Date:  2012-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.